247 related articles for article (PubMed ID: 18501085)
41. Therapeutic efficacy of combined PEGylated liposomal doxorubicin and radiofrequency ablation: Comparing single and combined therapy in young and old mice.
Andriyanov AV; Portnoy E; Koren E; Inesa S; Eyal S; Goldberg SN; Barenholz Y
J Control Release; 2017 Jul; 257():2-9. PubMed ID: 28215670
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study.
Yang FO; Hsu NC; Moi SH; Lu YC; Hsieh CM; Chang KJ; Chen DR; Tu CW; Wang HC; Hou MF
Asia Pac J Clin Oncol; 2018 Jun; 14(3):198-203. PubMed ID: 29045014
[TBL] [Abstract][Full Text] [Related]
43. Lipid bubbles combined with low-intensity ultrasound enhance the intratumoral accumulation and antitumor effect of pegylated liposomal doxorubicin
Yokoe I; Omata D; Unga J; Suzuki R; Maruyama K; Okamoto Y; Osaki T
Drug Deliv; 2021 Dec; 28(1):530-541. PubMed ID: 33685314
[TBL] [Abstract][Full Text] [Related]
44. Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.
Fujisaka Y; Horiike A; Shimizu T; Yamamoto N; Yamada Y; Tamura T
Jpn J Clin Oncol; 2006 Dec; 36(12):768-74. PubMed ID: 17095524
[TBL] [Abstract][Full Text] [Related]
45. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
[TBL] [Abstract][Full Text] [Related]
46. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
47. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).
Orditura M; Quaglia F; Morgillo F; Martinelli E; Lieto E; De Rosa G; Comunale D; Diadema MR; Ciardiello F; Catalano G; De Vita F
Oncol Rep; 2004 Sep; 12(3):549-56. PubMed ID: 15289836
[TBL] [Abstract][Full Text] [Related]
48. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
49. Pegylated liposomal doxorubicin in the treatment of breast cancer.
O'Shaughnessy JA
Clin Breast Cancer; 2003 Dec; 4(5):318-28. PubMed ID: 14715106
[TBL] [Abstract][Full Text] [Related]
50. Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin.
Castiñeiras I; Almagro M; Rodríguez-Lozano J; Fernández-Jorge B; Paradela S; Pozo JD; Fonseca E
J Dermatolog Treat; 2006; 17(6):377-80. PubMed ID: 17853313
[TBL] [Abstract][Full Text] [Related]
51. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K
Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682
[TBL] [Abstract][Full Text] [Related]
52. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors.
Schmitt CJ; Dietrich S; Ho AD; Witzens-Harig M
Ann Hematol; 2012 Mar; 91(3):391-7. PubMed ID: 21850390
[TBL] [Abstract][Full Text] [Related]
53. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.
Alba E; Ruiz-Borrego M; Margelí M; Rodríguez-Lescure A; Sánchez-Rovira P; Ruiz A; Mel-Lorenzo JR; Ramos-Vázquez M; Ribelles N; Calvo E; Casado A; Márquez A; Vicente D; García-Sáenz JA; Martín M
Breast Cancer Res Treat; 2010 Jul; 122(1):169-76. PubMed ID: 20361253
[TBL] [Abstract][Full Text] [Related]
54. Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice.
Zhao M; Ding XF; Shen JY; Zhang XP; Ding XW; Xu B
J Zhejiang Univ Sci B; 2017 Jan.; 18(1):15-26. PubMed ID: 28070993
[TBL] [Abstract][Full Text] [Related]
55. From conventional to stealth liposomes: a new frontier in cancer chemotherapy.
Cattel L; Ceruti M; Dosio F
Tumori; 2003; 89(3):237-49. PubMed ID: 12908776
[TBL] [Abstract][Full Text] [Related]
56. Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study.
Di Lorenzo G; Kreuter A; Di Trolio R; Guarini A; Romano C; Montesarchio V; Brockmeyer NH; De Placido S; Bower M; Dezube BJ
J Invest Dermatol; 2008 Jun; 128(6):1578-80. PubMed ID: 18185536
[No Abstract] [Full Text] [Related]
57. Anticancer Efficacy of the Combination of Berberine and PEGylated Liposomal Doxorubicin in Meth A Sarcoma-Bearing Mice.
Yahuafai J; Asai T; Oku N; Siripong P
Biol Pharm Bull; 2018; 41(7):1103-1106. PubMed ID: 29962406
[TBL] [Abstract][Full Text] [Related]
58. Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes.
Tahover E; Patil YP; Gabizon AA
Anticancer Drugs; 2015 Mar; 26(3):241-58. PubMed ID: 25415656
[TBL] [Abstract][Full Text] [Related]
59. Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis.
Lorusso D; Sabatucci I; Maltese G; Lepori S; Tripodi E; Bogani G; Raspagliesi F
Tumori; 2019 Aug; 105(4):282-287. PubMed ID: 30917765
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin.
Song H; Zhang J; Han Z; Zhang X; Li Z; Zhang L; Fu M; Lin C; Ma J
Cancer Chemother Pharmacol; 2006 May; 57(5):591-8. PubMed ID: 16133530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]